SecBot SecBot
Biotech Drug Report Generated Aug 31, 2026

XmAb819

XNCR·Xencor Inc
NEUTRAL
Drug Impact Rating5/10
Trial phase
Phase 1
Time to market
Unknown, pivotal study start is planned for 2027, meaning FDA approval would likely be several years away if Phase 2/3 data are positive.
Why 5/10
The next hard, dated catalyst is the ESMO 2026 proffered paper oral presentation of Phase 1 dose-expansion data (likely October 2026). This is Phase 1 data, not a pivotal readout, and Xencor has a broader pipeline of partnered and proprietary XmAb programs, so XmAb819 is not the company's sole value driver. ImpactScore is 5.
Actionable Insight NEUTRAL

Watch the ESMO 2026 oral presentation (likely October 2026) for updated Phase 1 dose-expansion data, specifically whether the 25% ORR holds or improves in a larger cohort and whether the safety profile (primarily Grade 1-2 CRS, rash, GI events) remains manageable. The pivotal study start in 2027 is the next major milestone after that. XNCR's ~$26 stock price already reflects a mean analyst target of $29, limiting near-term upside absent a clear data beat.

Price Chart

Loading chart...

Executive Summary

XmAb819 is a first-in-class ENPP3 x CD3 bispecific T-cell engager from Xencor (NASDAQ:XNCR), in Phase 1 testing for advanced clear cell renal cell carcinoma (ccRCC). Initial dose-escalation data showed a 25% objective response rate in heavily pretreated patients, meeting internal criteria to proceed to dose expansion. The drug is on track for a pivotal study start in 2027. Xencor trades at ~$26.20 with a market cap supported by a broader XmAb platform and partnered programs. The next catalyst is an ESMO 2026 oral presentation of updated Phase 1 data. While early efficacy is promising, the drug remains early-stage with a long path to market, and the stock already reflects a strong analyst consensus (17 Buy/Strong Buy out of 20 analysts) and a mean price target of $29 (8.8% upside).

How It Works

XmAb819 is a bispecific antibody, a single engineered molecule with two arms. One arm binds to ENPP3, a protein found on the surface of kidney cancer cells (clear cell renal cell carcinoma). The other arm grabs CD3, a protein on immune T-cells. This brings T-cells right up to the cancer cells, triggering the immune system to kill them. It uses Xencor's proprietary "2+1" format, which gives it two binding sites for the tumor target (for tighter grip) and one for the T-cell.

Trial Status

XmAb819 is in a multicenter, open-label Phase 1 study (NCT05433142) combining dose escalation and dose expansion. As of a September 19, 2025 data cut-off, 69 patients had received XmAb819 across 10 intravenous and 5 subcutaneous dose cohorts. Initial dose-escalation results were presented at the AACR-NCI-EORTC Conference in October 2025, showing a 25% objective response rate (ORR) in unselected, heavily pretreated clear cell renal cell carcinoma (ccRCC) patients. The drug met internal criteria to advance into the dose-expansion phase. A proffered paper oral presentation at ESMO 2026 has been accepted for updated Phase 1 results.

The Two-Sided Case

▲ Bull Case4
First-in-class mechanism: XmAb819 is the only ENPP3 x CD3 bispecific in clinical development, targeting an antigen highly expressed on ccRCC cells with a differentiated 2+1 format for tumor selectivity.
Encouraging early efficacy: 25% ORR in heavily pretreated, unselected ccRCC patients at the initial dose-escalation data cut is competitive for this refractory population and met internal criteria to advance to dose expansion.
Strong institutional support: BlackRock ($220M), PRIMECAP ($164M), RTW Investments ($109M), and RA Capital ($85M) are top holders as of Q2 2026, and multiple funds added or doubled positions in the quarter.
Broad platform value: Xencor's XmAb Fc technology platform generates partnered revenue and supports a pipeline of >20 clinical programs, reducing single-asset risk.
▼ Bear Case5
Early-stage risk: XmAb819 is still in Phase 1 dose expansion, the pivotal study hasn't started yet (planned for 2027). Approval is years away and attrition risk for Phase 1 oncology assets is high.
Safety concerns: Cytokine release syndrome (CRS), rash, and GI toxicities were the most common adverse events. While primarily Grade 1-2, CRS is a known risk for T-cell engagers and could limit dosing or require mitigation strategies.
Competitive ccRCC landscape: Multiple approved therapies exist (TKIs, checkpoint inhibitors, HIF-2α inhibitors) and other bispecifics/T-cell engagers are in development for RCC, creating a crowded target.
Insider selling: Director Ellen Feigal sold shares under a 10b5-1 plan at $13.06 in June 2026, and director Kevin Gorman also sold at ~$12.31, though these were pre-planned sales, the low price relative to current ~$26 raises questions about timing.
Elevated short volume: The weighted short-volume ratio was 0.65 over the last 58 sessions, indicating elevated bearish flow.

Upcoming Catalysts

  • ESMO 2026 proffered paper oral presentation of updated Phase 1 dose-expansion data (likely October 2026)
  • Pivotal study start planned for 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Xencor Inc 8-K XNCR ·Originating report

Sources · 8

Hover a chip for the title
1 xencor.com2 investors.xencor.com3 investors.xencor.com4 clinicaltrials.gov5 xencor.com6 businesswire.com7 targetedonc.com8 biopharmaboardroom.com